Status:

Do Not Prescribe (DNP), Red

Decision Date:

February 2022

Comments

RED: Monotherapy for the first-line treatment of adults with blastic plasmacytoid dendritic cell neoplasm. (Decision date - February 2022)

Do Not Prescribe (DNP): NICE TA782 - Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) (Decision date - April 2022)

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again